---

Treatment of Acute Pancreatitis

---

1. Diagnosis & Severity Assessment

1. Characteristic epigastric pain (often radiating to the back)
2. Serum lipase or amylase >3x upper limit of normal (lipase preferred - higher sensitivity/specificity)
3. Characteristic findings on imaging (CT/MRI)

---

2. Fluid Resuscitation (MOST IMPORTANT EARLY INTERVENTION)

• Lactated Ringer's (LR) is preferred over normal saline (NS)
  • LR is more physiologic (balanced electrolyte solution)
  • LR may provide anti-inflammatory effects via lactate-mediated mechanisms
  • A 2025 meta-analysis of 6 RCTs (n=1,500 patients) showed LR vs. NS: significantly lower risk of moderate-to-severe AP (OR 0.48; 95% CI 0.34-0.67), shorter hospital stay, lower ICU admission rate (RR 0.42), and fewer local complications (Zhao et al., Int J Surg 2025, PMID 40085761)
• Rate: Aggressive resuscitation - typically 250-500 mL/h during the first 12-24 hours in moderate-severe disease; careful goal-directed therapy to avoid overhydration
• Titrate to: urine output >0.5 mL/kg/h, HR <100, MAP >65 mmHg, BUN trending down

---

3. Pain Management

• Adequate analgesia is essential; IV opioids (morphine, hydromorphone, fentanyl) are widely used and are safe
• NSAIDs and acetaminophen can supplement but are often insufficient alone in acute presentations
• There is no evidence that one analgesic is superior to another specifically for pancreatitis
• Epidural analgesia is an option in severe cases

---

4. Nutrition

• Mild AP: Oral diet should be restarted as soon as it is tolerated (often within 24-48 hours). There is no need to wait until pain resolves or amylase normalizes.
• Moderate-severe AP:
  • Early enteral nutrition within 24-72 hours of admission is associated with decreased mortality, organ failure, and infectious complications vs. delayed nutrition
  • Nasogastric (NG) or nasojejunal (NJ) tube feeding - RCTs show no significant difference in outcomes between gastric vs. jejunal delivery, so a nasogastric tube is acceptable
  • NPO initially if there is ileus or if the patient cannot tolerate any intake
  • TPN (parenteral nutrition) is reserved for cases where enteral feeding is not tolerated (refractory vomiting, intestinal obstruction, high-output fistula)
• Enteral nutrition maintains gut barrier function, reduces bacterial translocation, and reduces risk of infectious complications

---

5. Antibiotics

• Prophylactic antibiotics are NOT indicated in acute pancreatitis - this includes even severe or necrotizing pancreatitis without evidence of infection
• Harrison's (2025 ed.): "Prophylactic antibiotics are no longer recommended for severe acute pancreatitis"
• Antibiotics ARE indicated for:
  • Documented infected pancreatic necrosis (confirmed by FNA or gas on CT, or clinical deterioration with fever/leukocytosis)
  • Cholangitis (ascending cholangitis complicating biliary pancreatitis)
  • Other clear sources of bacterial sepsis
• Preferred agents for infected necrosis: carbapenems (imipenem, meropenem) or fluoroquinolones + metronidazole (good pancreatic tissue penetration)

---

6. Role of ERCP

• ERCP is indicated in:
  • Acute cholangitis complicating gallstone pancreatitis (urgent, within 24-72 hours)
  • Biliary obstruction with evidence of persistent common bile duct stones
• ERCP is NOT indicated in mild biliary pancreatitis without cholangitis or persistent biliary obstruction (does not improve outcomes and risks complications)
• Rectal indomethacin (NSAIDs) or pancreatic duct stenting is used to prevent post-ERCP pancreatitis in high-risk patients

---

7. Management of Complications

Pancreatic Necrosis

• Minimally invasive approach preferred (step-up approach)
  1. CT/EUS-guided percutaneous or endoscopic drainage as first step
  2. Video-assisted retroperitoneal debridement (VARD) or endoscopic necrosectomy if drainage fails
  3. Open surgical necrosectomy - last resort (high morbidity/mortality)
• Intervention ideally delayed >4 weeks to allow "walled-off necrosis" (WON) to mature (better defined walls, safer to drain)
• FNA is now used less routinely; clinical judgment + CT findings guide decisions

Pseudocyst

• Most resolve spontaneously
• Drainage indicated if: symptomatic (pain, gastric outlet obstruction), infection, enlarging, or >6 weeks without resolution
• Endoscopic (EUS-guided cyst-gastrostomy or cyst-duodenostomy) is preferred over surgical drainage

Pancreatic Ascites/Pleural Effusion

• From ductal disruption; ERCP with stenting ± somatostatin analogue

---

8. Special Situations

Biliary/Gallstone Pancreatitis

• Cholecystectomy should be performed before discharge (or at least during the same hospitalization) in mild disease to prevent recurrence
• In severe disease, cholecystectomy is deferred until recovery

Hypertriglyceridemia-induced Pancreatitis

• Insulin infusion or plasmapheresis to rapidly lower triglycerides (target <500 mg/dL)
• Fibrates and dietary fat restriction for long-term prevention

Alcohol-induced Pancreatitis

• Alcohol cessation counseling and treatment (reduces recurrence and progression to chronic pancreatitis)

---

9. ICU Indications

• Persistent organ failure (renal, respiratory, cardiovascular)
• APACHE II score >8 or Ranson score >3 at 48 hours
• Clinical deterioration despite initial management
• Septic shock from infected necrosis

---

10. Summary of Key Guideline Recommendations (2024-2025)

1. LR preferred over NS for fluid resuscitation
2. Early enteral nutrition within 24-72 hours
3. No prophylactic antibiotics in the absence of infection
4. Minimally invasive, step-up approach for infected necrosis
5. Cholecystectomy before discharge for biliary pancreatitis
6. ERCP only for cholangitis/biliary obstruction
7. Conservative management for sterile complications whenever possible

---

• Rosen's Emergency Medicine, 10th ed. - Chapter 77
• Maingot's Abdominal Operations - Chapter 55 (Complications of AP)
• Harrison's Principles of Internal Medicine, 22nd ed. (2025) - Chapter 7.39
• Washington Manual of Medical Therapeutics - Nutrition section
• ACG Guidelines 2024 (PMID 38857482)
• IAP/APA/EPC/IPC/JPS Revised Guidelines 2025 (PMID 40651900)
• Zhao et al., LR vs NS meta-analysis, Int J Surg 2025 (PMID 40085761)

---

UTI in Diabetic Patients with Chronic Smoking and Alcohol Use

---

1. Why This Patient is at Extreme Risk: Pathophysiology

Diabetes Mellitus

Chronic Alcohol Use

• Impairs neutrophil maturation in the bone marrow and depresses cell-mediated immunity
• Impairs neutrophil chemotaxis, phagocytosis, and intracellular killing
• Alcohol-related liver disease (cirrhosis) results in hypocomplementemia, reduced opsonization, and impaired Kupffer cell function
• Alcoholic patients are vulnerable to overwhelming gram-negative sepsis (E. coli bacteremia is common)
• Malnutrition associated with alcoholism impairs zinc-dependent immune functions
• Patients with liver disease/cirrhosis often develop spontaneous bacteremia predominantly with E. coli
• Textbook of Family Medicine, 9th ed.; Goodman & Gilman's Pharmacological Basis of Therapeutics

Chronic Smoking

• Smoking impairs mucosal immunity - reduces secretory IgA in mucosal surfaces
• Reduces Langerhans cell populations and alters mucosal immune defense
• Promotes oxidative stress, impairing neutrophil function
• Smoking-related COPD/bronchiectasis increases risk for concurrent respiratory infections (Gram-negatives, including Pseudomonas)
• Nicotine causes bladder urothelial changes - increased bacterial adherence
• Carcinogens in cigarette smoke predispose to bladder cancer (which itself is a risk factor for complicated UTI and obstruction)

---

2. Classification: This is a COMPLICATED UTI

• Metabolic disease (diabetes)
• Immunocompromised state (alcohol-related immune deficiency + smoking)
• High likelihood of functional urinary tract abnormality (diabetic cystopathy, neurogenic bladder)
• Risk of resistant organisms

"Complicated urinary tract infection occurs in individuals with functional or structural abnormalities of the genitourinary tract... Complicated UTI: infection in the setting of metabolic, immunocompromised, functional, or anatomic abnormality."

• Brenner and Rector's The Kidney, 2-Volume Set; Smith and Tanagho's General Urology

---

3. Microbiology - Organisms to Expect

---

4. Unique Complications in This Patient Population

Emphysematous Pyelonephritis (EPN)

• Life-threatening gas-forming necrotizing renal infection
• 95% of cases occur in diabetics (Kamei & Yamamoto, J Infect Chemother 2021)
• Gas in renal parenchyma or perirenal space on CT
• Organisms: E. coli (45-54%), Klebsiella (gas generated from glucose fermentation)
• High mortality: 7-20% with percutaneous drainage + antibiotics; up to 70% in fulminant disease
• Management: CT-guided percutaneous drainage + IV antibiotics + aggressive glycemic control; nephrectomy for non-responders
• Mortality rates: 50% with medical management alone vs. 13.5% with medical management + percutaneous drainage

Emphysematous Cystitis

• Less severe than EPN; gas in bladder wall
• 67% of cases have DM; E. coli (58%), Klebsiella (21%)
• Treatment: antibiotics + bladder drainage + glycemic control; surgical intervention only in 10%
• Overall mortality 7%

Renal Papillary Necrosis

• Seen particularly during acute pyelonephritis in diabetics
• Also with analgesic nephropathy, sickle cell disease, obstruction
• Presents as flank pain, hematuria, sloughing of papillae (visible on imaging as "ring shadow" on IVU or filling defects on CT)

Perinephric / Intrarenal Abscess

• More common in diabetics; higher risk with alcoholism-related immune depression
• Often requires CT-guided drainage + 4-6 weeks of antibiotics

Renal Carbuncle

• Due to hematogenous spread of Staphylococcus aureus (especially in diabetics)
• Treat with anti-staphylococcal antibiotics (nafcillin/oxacillin or vancomycin if MRSA suspected)

Xanthogranulomatous Pyelonephritis

• Chronic destructive renal infection; associated with urolithiasis and recurrent UTI
• Higher incidence in diabetics; usually requires nephrectomy

Urosepsis

• Diabetic patients have higher rates of bacteremia complicating pyelonephritis
• Gram-negative bacteremia (E. coli) common in alcoholics
• Combined patient is at very high risk for septic shock

---

5. Asymptomatic Bacteriuria (ASB) in Diabetics

• Pregnancy
• Pre-urological procedure
• Renal transplant recipient (within first month)
• Washington Manual of Medical Therapeutics; Smith and Tanagho's General Urology; Campbell Walsh Wein Urology

---

6. Diagnosis

Urine Studies

• Urinalysis: Pyuria (>5 WBC/hpf), bacteriuria, nitrite positive (Gram-negatives only), leukocyte esterase
• Urine culture with sensitivity: Mandatory in ALL complicated UTI - do NOT start empirical antibiotics without sending cultures first
• Threshold: ≥10⁵ CFU/mL symptomatic; ≥10² CFU/mL with catheter or suprapubic aspiration

Blood Tests

• CBC (leukocytosis, bandemia suggest severe infection)
• BMP/RFT (renal function - especially important given diabetic nephropathy risk)
• Blood glucose, HbA1c (glycemic control assessment)
• Blood cultures (if febrile or sepsis suspected - particularly in this patient)
• LFTs, coagulation profile (alcohol-related liver disease)
• CRP/procalcitonin (markers of severity)

Imaging

• Ultrasound KUB: First-line for obstruction, hydronephrosis, stones, perinephric abscess
• CT abdomen/pelvis (contrast-enhanced): Indicated if:
  • Failure to respond to antibiotics after 48-72 hours
  • Suspected EPN, abscess, papillary necrosis, or obstruction
  • Gas on plain X-ray or U/S
  • Sepsis with unknown source

---

7. Treatment

General Principles

1. Always culture urine BEFORE starting antibiotics
2. This patient requires hospitalization - oral outpatient therapy is NOT recommended for complicated UTI in a diabetic
3. Strict glycemic control is essential - hyperglycemia impairs immune response and drives emphysematous infections
4. No TMP-SMX as first choice in diabetics on oral hypoglycemic drugs - it potentiates hypoglycemia
5. Alcohol withdrawal monitoring - a hospitalized chronic alcoholic must be monitored for withdrawal (CIWA protocol, thiamine supplementation)
6. Avoid NSAIDs - nephrotoxic, especially with diabetic nephropathy

Antibiotic Treatment

• Smith and Tanagho's General Urology, Table 14-6; Kamei & Yamamoto, J Infect Chemother 2021 (PMID 34024733)

SGLT2 Inhibitors (Diabetic Patients on These Medications)

• SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) significantly increase genital mycotic infections, but NOT the rate of UTI, pyelonephritis, or urosepsis significantly
• However, they promote glucosuria, which may lower threshold for candidal cystitis
• Consider temporarily holding SGLT2 inhibitors during acute illness (sick-day rule)

---

8. Special Considerations for the Alcoholic Patient

---

9. Special Considerations for the Chronic Smoker

---

10. Indications for ICU Admission / Urgent Intervention

• Signs of septic shock (hypotension, tachycardia, altered mental status, lactate >2 mmol/L)
• Emphysematous pyelonephritis (requires urgent CT + ICU-level care)
• Bilateral EPN or EPN with renal failure
• Urosepsis with DIC or multi-organ failure
• Failure to improve in 48-72 hours despite appropriate IV antibiotics

---

11. Prevention and Long-term Management

---

• Smith and Tanagho's General Urology, 19th ed. - Chapter 14 (UTIs in Diabetes)
• Brenner and Rector's The Kidney, 2-Volume Set - Chapter 36 (UTI definitions, host defenses); Chapter emphysematous infections
• Harrison's Principles of Internal Medicine, 22nd ed. (2025) - Chapter on Diabetes Complications (Infections)
• Comprehensive Clinical Nephrology, 7th ed. - Diabetic patient with CKD and UTI
• Textbook of Family Medicine, 9th ed. - Acquired conditions predisposing to infection
• Washington Manual of Medical Therapeutics - Asymptomatic bacteriuria
• Kamei & Yamamoto, "Complicated UTIs with Diabetes Mellitus," J Infect Chemother 2021 (PMID 34024733)

1. Entry point - Suspected UTI with presenting symptoms (dysuria, frequency, flank pain, fever, CVA tenderness)
2. First decision node - Identifies complicating factors (diabetes, pregnancy, male sex, immunosuppression from alcohol/smoking/HIV, structural anomalies, catheters, CKD, renal transplant)
3. Branching:
   • No complicating factors → Uncomplicated UTI → outpatient oral therapy
   • Complicating factors present → Complicated UTI → severity stratification
4. Three-tier severity classification:
   • 🟡 Mild - Afebrile/low-grade fever, tolerating orals, no systemic signs → oral fluoroquinolone, outpatient with 48-72h follow-up
   • 🟠 Moderate - Fever >38°C, pyelonephritis, nausea/vomiting, early leukocytosis → hospital admission, IV antibiotics, imaging
   • 🔴 Severe/Critical - SIRS criteria, hypotension, sepsis/septic shock, suspected EPN → ICU, broad-spectrum carbapenems, CT imaging, source control
5. Red flags box - Triggers for immediate escalation: emphysematous pyelonephritis, perinephric abscess, papillary necrosis, urosepsis with DIC, failure to improve in 48-72h
6. Follow-up & prevention - Repeat cultures, HbA1c optimization, smoking/alcohol cessation, post-void residual monitoring, suppressive antibiotics if recurrent

---

Ureteric / Renal Colic

Terminology note: "Renal colic" is technically a misnomer. The correct term is ureteric colic - the pain arises from hyperperistalsis of the ureteric smooth muscle against an obstructing stone, not from the kidney itself. However, both terms are widely used in clinical practice. - Bailey and Love's Short Practice of Surgery, 28th ed.

---

1. Epidemiology & Stone Types

• Annual incidence: >1 per 1000 persons in industrialized nations; lifetime risk ~10% in women, ~15% in men
• Incidence peaks in the 4th-5th decades; prevalence has increased from 3% (1970s) to >5% (current), likely due to dietary and lifestyle changes
• Obesity (BMI >30) significantly increases stone risk

---

2. Clinical Presentation

Symptoms

• Ureteric colic: Sudden-onset, severe, colicky flank pain radiating to the groin, scrotum, or labia (following the path of the ureter)
• Pain is typically excruciating, unrelenting (patient cannot find a comfortable position - vs. peritonitis where patient lies still)
• Lower ureteric stones (near UVJ): cause urgency, frequency, dysuria mimicking cystitis
• Nausea and vomiting (reflex, very common)
• Haematuria: gross or microscopic in most cases
• Calculuria: passing of sand or gravel in urine

Radiation of Pain by Stone Location

Key clinical point

"Ureteric colic does NOT radiate to the chest or the back of the leg." - Bailey & Love

---

3. Differential Diagnosis

Critical: AAA must always be excluded in the middle-aged/elderly patient presenting with flank pain - especially if the pain is not colicky and there is a pulsatile mass.

---

4. Investigations

Emergency Setting

• Dipstick: haematuria (present in 85-90%, but can be absent), pyuria
• Mid-stream urine culture if pyuria/fever present
• Urine pregnancy test in women of reproductive age (mandatory - ectopic pregnancy)

• FBC (leukocytosis suggests infection), U&E/Cr (renal function), eGFR
• Serum calcium, phosphate, uric acid (initial metabolic screen)
• Serum lactate + blood cultures if sepsis suspected

Non-Emergency / Metabolic Evaluation

• 24-hour urine collection: volume, calcium, oxalate, uric acid, citrate, phosphate, creatinine
• Serum: calcium, phosphate, uric acid, PTH (if hypercalcaemia)
• Stone analysis (if passed or retrieved)
• Urine pH (low = uric acid; high = struvite/RTA)

---

5. Complications

---

6. Management

6a. Emergency Management - Immediate Pain Relief

• Ketorolac 30 mg IV or diclofenac 75 mg IM
• NSAIDs reduce pain AND decrease ureteral/intrarenal pressure (by reducing prostaglandin-mediated ureteric spasm and urine production)
• A 2025 Cochrane systematic review (29 RCTs, 3,593 participants) confirmed NSAIDs significantly reduce renal colic pain vs. placebo (MD -3.84 cm VAS at 30 min); no one NSAID was clearly superior to another - (Afshar et al., Cochrane 2025, PMID 40084512)
• Oral route when tolerated; parenteral when nausea/vomiting prevents oral intake

• Morphine IV, pethidine, fentanyl
• Used when NSAIDs are contraindicated (renal impairment, peptic ulcer) or insufficient
• There is NO evidence that morphine causes more ureteric spasm than other opioids - it is safe and appropriate - Rosen's Emergency Medicine
• Antiemetics (ondansetron, metoclopramide) should accompany opioids

• NOT recommended as routine - evidence does not support their use for ureteric colic pain relief - Bailey & Love

• IV fluids for hydration but forced diuresis does NOT improve stone passage rates and may worsen pain

6b. Conservative Management (Watchful Waiting)

• Appropriate for small stones (<5 mm) that are likely to pass spontaneously
• Spontaneous passage rates:
  • <4 mm stones: ~90% pass spontaneously
  • 5-7 mm: ~50% pass spontaneously

  • 7 mm: <25% pass; intervention usually required

• Stone <5 mm (distal ureteric)
• Well-controlled pain with oral analgesics
• No signs of infection
• Normal renal function
• Patient compliant with follow-up

6c. Medical Expulsive Therapy (MET)

• 0.4 mg once daily
• Causes smooth muscle relaxation of distal ureteric musculature
• Indicated for distal ureteric stones >5 mm
• Also used to assist passage of fragments following ESWL

• PDE-5 inhibitors (sildenafil/tadalafil): stone expulsion rate 2.7x better than alpha-blocker alone; also shorter expulsion time
• Corticosteroids: 2.7x higher stone expulsion rate
• Phytotherapy: 3.1x higher expulsion rate

6d. Surgical/Interventional Management

1. Failure of conservative management (pain uncontrolled)
2. Stone size >10 mm (unlikely to pass spontaneously)
3. Obstructed infected kidney / pyonephrosis (EMERGENCY)
4. Impaired renal function / solitary kidney
5. Bilateral obstructing stones
6. High-risk occupation (pilots, sailors, locomotive drivers)
7. Patient preference

• Percutaneous nephrostomy (PCN): Radiologically guided drain into the renal pelvis - preferred in septic/unstable patients
• Retrograde ureteric stenting (JJ stent): Cystoscopy + fluoroscopy-guided placement; provides drainage past the obstruction
• Blood and urine cultures MUST be taken first; empirical broad-spectrum antibiotics started immediately

• Non-invasive; introduced by Christian Chaussy in 1980
• Stone localised by fluoroscopy or ultrasound; focused shock waves fragment the stone
• Efficacy decreases with increasing stone burden
• Steinstrasse is a recognised complication (stone fragments queuing in ureter); usually pass spontaneously but may obstruct
• "Clinically insignificant residual fragments" (≤4 mm) may not clear in 20-40% of cases and form a nidus for regrowth

• Semirigid or flexible ureterorenoscopes (URSs)
• Working channels for laser/pneumatic lithotripsy, graspers, baskets
• Has largely replaced ESWL for many ureteric stones
• Complications: ureteric perforation, avulsion, retropulsion

• Involves creating a skin-to-pelvicalyceal tract (usually prone position)
• Fluoroscopy or USS guided; posterolateral calyx entry
• Complications: bleeding (may require embolisation), infection, pleural violation (supracostal approach)

---

7. Stone-Specific Management and Prevention

General Prevention for All Stone Types

• Fluid intake: Target urine output >2.5 L/day (most important intervention)
• Avoid dehydration (hot climates, exercise, occupational fluid restriction)
• Dietary: reduce salt, limit animal protein; maintain normal calcium intake (low calcium diet WORSENS oxalate stones)
• Body weight control
• Treat underlying metabolic disorders

---

8. Indications for Hospital Admission

---

• Bailey and Love's Short Practice of Surgery, 28th ed. - Chapters 81 (Urinary symptoms) & 82 (Urolithiasis)
• Goldman-Cecil Medicine, International Edition - Chapter on Nephrolithiasis
• Rosen's Emergency Medicine, 10th ed. - Renal stone management
• Campbell Walsh Wein Urology - Stone surgery chapters
• Afshar et al., "NSAIDs for acute renal colic," Cochrane Database Syst Rev, 2025 (PMID 40084512)
• Taheri et al., "Combination MET for distal ureteral stone," BMC Urol, 2025 (PMID 39875883)

---

Antifungal Creams (Topical Antifungal Agents)

---

1. Mechanisms of Action

Ergosterol Synthesis Pathway and Drug Targets

---

2. Drug Classes and Individual Agents

Class 1 - Azoles (Imidazoles - Topical)

---

Class 2 - Allylamines and Benzylamines

Key advantage of terbinafine: Treatment course for tinea corporis/cruris can be shortened to 1 week (vs. 2-4 weeks for azoles). Clinical relapse rates are significantly lower. - Dermatology, 5th ed. (Bolognia et al.)

Resistance alert: In some geographic regions (notably India), Trichophyton species have developed increasing terbinafine resistance due to mutations in the squalene epoxidase gene. Local resistance patterns should guide choice.

---

Class 3 - Polyenes

Nystatin is not well absorbed from the GI tract when taken orally - this is used therapeutically to treat intestinal/anogenital candidiasis and candidal diaper dermatitis. - Dermatology, 5th ed.

---

Class 4 - Ciclopirox Olamine

• Spectrum: Broad - dermatophytes, Malassezia, Candida, actinomycetes, molds, and even some Gram-positive/Gram-negative bacteria
• Formulations: 0.77% cream, gel, lotion (Loprox); 8% nail lacquer (Penlac) for onychomycosis
• Indications: Tinea corporis, tinea pedis, tinea cruris, onychomycosis (nail lacquer), tinea versicolor, mucocutaneous candidiasis, seborrheic dermatitis
• More effective than azoles, allylamines, and benzylamines against Candida specifically

---

Class 5 - Miscellaneous Topical Antifungals

---

3. Clinical Indications by Condition

---

4. When Topical Fails - Indications for Systemic Therapy

• Extensive skin involvement (>2 body areas)
• Tinea capitis (ALWAYS requires systemic - topical antifungals are ineffective for scalp ringworm)
• Tinea unguium / onychomycosis (nail - oral terbinafine or itraconazole preferred for higher cure rates)
• Fungal folliculitis / Majocchi granuloma (deep follicular involvement)
• Immunocompromised patient
• Failed adequate topical therapy

---

5. Important Warnings and Precautions

Combination Antifungal-Corticosteroid Products (e.g., Clotrimazole/Betamethasone = Lotrisone)

These should be avoided. Use of potent corticosteroid combinations with antifungals frequently produces:

• Tinea incognita - atypical, widespread tinea with no ring border, no central clearing, eczematous center; can be mistaken for eczema or psoriasis
• Majocchi granuloma - deep follicular infection from steroid-enhanced fungal invasion
• Spread of infection due to immunosuppression
• Andrews' Diseases of the Skin, Clinical Dermatology

Resistance

• Azole resistance is increasing, especially in immunocompromised patients on prolonged therapy (mechanism: mutation in 14-α-demethylase gene; efflux pumps; reduced ergosterol)
• Candida auris - emerging multidrug-resistant pathogen; often azole-resistant; associated with healthcare settings
• Terbinafine resistance in Trichophyton spp. is rising in South Asia

Pregnancy

• Topical azoles (clotrimazole, miconazole) are generally considered safe
• Topical terbinafine: use with caution; avoid in first trimester if possible
• Oral antifungals should be avoided in pregnancy where possible

---

6. Quick Comparison - Which Cream for What?

---

• Katzung's Basic and Clinical Pharmacology, 16th ed. - Chapter on Antifungal Agents / Topical Preparations
• Dermatology, 5th ed. (Bolognia et al.) - Chapter on Topical Antifungal Agents
• Andrews' Diseases of the Skin, Clinical Dermatology - Treatment of Tinea Corporis
• Lippincott Illustrated Reviews: Pharmacology - Antifungal Mechanisms
• Harrison's Principles of Internal Medicine, 22nd ed. (2025) - Candidiasis and Dermatophytosis
• Medical Microbiology, 9th ed. - Antifungal Agent Classes and Ergosterol Pathway